Cancer and Leukemia Group B - The Ohio State University

癌症和白血病 B 组 - 俄亥俄州立大学

• 批准号: 7048482
• 负责人: CLARA D BLOOMFIELD
• 金额: $ 37.49万
• 依托单位: OHIO STATE UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 1998
• 资助国家: 美国
• 起止时间: 1998-04-16 至 2009-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7048482
• 关键词: AIDS related neoplasm /cancer; antineoplastics; bone marrow transplantation; breast neoplasms; cancer prevention; cancer registry /resource; clinical research; clinical trial phase I; clinical trial phase II; clinical trial phase III; combination cancer therapy; combination chemotherapy; cooperative study; drug screening /evaluation; early diagnosis; gastrointestinal neoplasms; health care cost /financing; hormone therapy; human subject; human therapy evaluation; leukemia; lymphoma; melanoma; neoplasm /cancer chemotherapy; neoplasm /cancer diagnosis; neoplasm /cancer education; neoplasm /cancer epidemiology; neoplasm /cancer genetics; neoplasm /cancer immunotherapy; neoplasm /cancer radiation therapy; neoplasm /cancer surgery; neoplasm /cancer vaccine; prostate neoplasms; psychological aspect of cancer; quality of life; respiratory neoplasm

DESCRIPTION (provided by applicant): The purpose of this grant is to support the scientific and clinical activities of Cancer and Leukemia Group B (CALGB) by providing necessary infrastructure to the CALGB program at The Ohio State University (OSU). The multidisciplinary collaborative research approach at OSU has a tract record of providing more effective methods of prevention, detection and treatment of adult cancer, with a particular focus on breast cancer, gastrointestinal cancers, genitourinary malignancies, hematologic malignancies, lung cancer and melanoma. This research focuses the efforts of medical and hematologic oncologists, surgeons, radiotherapists, transplanters, psychiatrists, pathologists, cytogeneticists, translational laboratory scientists, basic scientists, statisticians, epidemiologists, nurses, pharmacists, and clinical research associates on well designed and conducted studies asking interrelated clinical and basic science questions whose answers contribute significantly to patient care and to reduction of cancer within populations at increased risk. Included in this project are: 1) the exploration of new therapeutic agents, and their associated toxicities, in Phase I, II and III clinical trials; 2) the evaluation of efficacy and toxicity of new regimens including combinations of new and old agents in an effort to exploit synergistic combinations more effectively; 3) the development of multi-modal approaches to specific tumor problems using surgical, immunological and radiotherapeutic measures in optimal combinations; 4) the involvement of pertinent basic science disciplines such as molecular genetics, biochemistry, pharmacology, immunology and biostatistics in the formulation and execution of specific therapy protocols; 5) the improvement of cancer care in the community by using these protocols to educate pre- and post-doctoral students, nurses, allied medical personnel and physicians, 6) the evaluation of biologic studies in correlation with clinical endpoint to develop more rationally based cancer management, 7) the evaluation of cancer controls efforts such as early detection, and 8) the study of the psycho-social aspects of cancer. Under the overall coordination of Clara D. Bloomfield, M.D., OSU contributes to CALGB activities through patient accrual to protocols, development and leadership of research protocols, leadership and participation in the scientific and administrative committees of CALGB, housing of multiple CALGB core laboratories and facilities, CALGB meeting participation and authorship on Group publications. In addition, OSU performs institutional pilots and provides lab data that lead to new CALGB studies. Support of this program should increase our ability to prevent, detect, treat and cure adult cancer and improve the quality of life of cancer survivors.

描述（由申请人提供）：这笔赠款的目的是通过为俄亥俄州立大学（OSU）的CALGB计划提供必要的基础设施来支持癌症和白血病B组（CALGB）的科学和临床活动。 OSU的多学科协作研究方法具有提供更有效的预防，检测和治疗成人癌症的方法，特别着重于乳腺癌，胃肠道癌，泌尿生殖性恶性肿瘤，血液学恶性肿瘤，肺癌，肺癌和黑色素瘤。这项研究重点是医学和血液学肿瘤学家，外科医生，放射治疗师，移植者，精神科医生，病理学家，病理学家，细胞遗传学家，转化实验室科学家，基础科学家，统计学家，流行病学家，护士，护士，药学家，药剂师和临床研究协会，以促进临床和临床研究协会，以促进癌症和临床研究，以促进癌症的研究协会，以对癌症进行挑战，以对癌症进行挑战，以促进癌症的研究，以促进癌症科学的研究，以促进癌症的研究，并在癌症中进行了挑战，以促进癌症的研究，以促进癌症的研究，并在癌症中进行了挑战，并在癌症中进行了挑战，以促进癌症的研究协会，以促进癌症的研究，并在癌症中进行了挑战。风险增加。该项目中包括：1）在第一阶段，II和III临床试验中探索新的治疗剂及其相关毒性； 2）评估新方案的疗效和毒性，包括新旧代理的组合，以更有效地利用协同组合； 3）在最佳组合中采用手术，免疫和放射治疗方法来开发多模式方法来解决特定肿瘤问题； 4）相关基础科学学科的参与，例如分子遗传学，生物化学，药理学，免疫学和生物统计学，参与了特定治疗方案的制定和执行； 5）通过使用这些方案来教育社区癌症护理的改善，教育前后博士后学生，护士，联盟医学人员和医生，6）与临床终点相关的生物学研究评估，以发展基于理性的癌症管理，7）7）7）对早期检测的评估，例如早期检测，以及8）癌症的癌症研究。在医学博士Clara D. Bloomfield的整体协调下，OSU通过患者应计的患者应对研究方案，研究方案的发展和领导才能为CALGB的方案，领导和参与CALGB的科学和行政委员会的参与，多个Calgb核心实验室和设施的住房，Calgb核心实验室和设施，CALGB会议的参与以及对小组出版物的参与。此外，OSU还执行机构飞行员，并提供实验室数据，从而导致新的CALGB研究。该计划的支持应提高我们预防，检测，治疗和治愈成人癌症并改善癌症幸存者生活质量的能力。